Assessment of an Apo-1/Fas Promoter Polymorphism in Korean Schizophrenia Patients
![]() |
Kim, Soon-Ae
(Kohwang Medical Research Institute, College of Medicine, Kyung Hee University)
Kim, Youn-Jung (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) Choe, Bong-Keun (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) Lee, Hee-Jae (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) Kim, Jong-Woo (Seoul National University Mental Hospital) Park, Jong-Deuk (Kimcheon Medical Hospital) Kim, Chang-Ju (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) Park, Seung-Joon (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) Jung, Jee-Chang (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) Chung, Joo-Ho (Kohwang Medical Research Institute, College of Medicine, Kyung Hee University) |
1 | Catts VS, Catts SV. Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene? Schizophr Res 41(3): 405-415, 2000 |
2 | Harrison PJ. Schizophrenia: a disorder of neurodevelopment? Curr Opin. Neurobiol 7(2): 285-289, 1997 |
3 | Seidl R, Fang-Kircher S, Bidmon B, Cairns N, Nubec G. Apoptosisassociatedproteins p53 and Apo-l/Fas (CD95) in brains of adult patients with Down syndrome. Neurosci Lett 260(1): 9 -12, 1999 |
4 | DelaMonte SM, Sohn YK, Ganju N, Wands JR. p53- and CD95associated apoptosis in neurodegenerative diseases. Lab Invest 78(4): 401-411, 1995 |
5 | Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-l/Fas (CD95) gene. Mol Immunol 34(8-9): 577-582, 1997 |
6 | Huang QR, Danis V, Lassere M, Edmonds J, Manolios N. Evalulation of a new Apo-l/Fas promoter polymorphism in rhuemtoid arthritis and systemic lupus erythematosus patients. Rhematology (Oxford) 38(7): 645-651, 1999 |
7 | Mortensen PB. The incidence of cancer in schizophrenic patients. J Epulemiol Community Health 43(1): 43-47, 1989 |
8 | Nagata S. Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Land B Bioi Sci 345 (1313): 281- 287, 1994 |
9 | Shuai K. Interferon-activated signal transduction to the nucleus. Curr Opin Cell Bioi 6(2): 253 -259, 1994 |
10 | DelaMonte SM, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152(1): 73 - 83, 1995 |
11 | Cheng J, Liu C, Koopman WJ, Mountz JD. Characterization of human Fas gene. Exonlintron organization and promoter region. J Immunol 154(3): 1239-1245, 1995 |
12 | Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P. Constitutive and induced expression of Apo-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69(4): 415 - 429, 1993 |
13 | Rudert F, Visser E, Forbes L, Lindrige E, Wang Y, Watson J. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/Apo-1) gene. DNA Cell Bioi 14(11): 931-937, 1995 |
14 | Mortensen PE. The occurrence of cancer in first admitted schizophrenic patients. Schizophr Res 12(3): 185-194, 1994 |
15 | Huang QR, Teutsch SM, Buhler MM, Bennetts BH, Heard RN, Manolios N, Stewart GJ. Evaluation of the apo-l/Fas promoter Mva I polymorphism in multiple sclerosis. Mult SeZer 6(1): 1418, 2000 |
![]() |